Author's response to reviews Title: Transdermal rotigotine for the perioperative management of restless legs syndrome Authors:
نویسندگان
چکیده
1) Study's objective is "To assess rotigotine transdermal patch for the perioperative management of moderate to severe RLS". To assess what? Efficacy? Feasibility of use? The objective of this posthoc analysis was to assess the feasibility of use of rotigotine transdermal patch for the perioperative management of moderate to severe RLS. Efficacy data for the entire study population, including patients who did not undergo surgery were published elsewhere (references 18, 19, 20 of the manuscript). Visits throughout the maintenance phase of this 5-year study were scheduled at monthly intervals during the first year and at 3-monthly intervals thereafter. As stated in the methods part, no prespecified efficacy assessments (e.g. IRLS scores) were available for the perioperative period. Sentence in the abstract was changed to: To assess the feasibility of use of rotigotine transdermal patch for the perioperative management of moderate to severe RLS, long-term data... 2) In the conclusions, the sentence "This suggests that rotigotine transdermal patch may be a suitable alternative in situations where administration of oral treatments is limited or contraindicated" is too speculative and is not based on study results. It should be removed. We agree that the broad expression “situations” may be slightly speculative in the light of the data presented and we included perioperative situations. Sentence was
منابع مشابه
Transdermal rotigotine for the perioperative management of restless legs syndrome
BACKGROUND Immobilisation, blood loss, sleep deficiency, and (concomitant) medications during perioperative periods might lead to acute exacerbation of symptoms in patients with the restless legs syndrome (RLS). Continuous transdermal delivery of the dopamine agonist rotigotine provides stable plasma levels over 24 h and may provide RLS patients with a feasible treatment option for perioperativ...
متن کاملRotigotine Transdermal Patch for the Treatment of Restless Legs Syndrome
Rotigotine, a nonergot dopamine agonist, has been developed as a novel transdermal formulation. The rotigotine transdermal patch has received EMA and FDA marketing authorization for the treatment of adult patients with early or advanced Parkinson’s disease or with moderate-to-severe restless legs syndrome (RLS). This review comprises an overview of the pharmacokinetics, the pharmacodynamics and...
متن کاملRotigotine transdermal system: a short review
Rotigotine (Neupro((R))) is a new non-ergolinic dopamine agonist transdermal patch that can be applied once daily. To date, it is approved for the treatment of early Parkinson's disease as monotherapy and has been shown to be effective in the treatment of advanced-stage Parkinson's disease and restless legs syndrome in several clinical trials. This review gives an overview of physical, chemical...
متن کاملAn Update on Pharmacological, Pharmacokinetic Properties and Drug–Drug Interactions of Rotigotine Transdermal System in Parkinson’s Disease and Restless Legs Syndrome
This narrative review reports on the pharmacological and pharmacokinetic properties of rotigotine, a non-ergolinic D₃/D₂/D₁ dopamine receptor agonist approved for the treatment of early- and advanced-stage Parkinson's disease (PD) and moderate to severe restless legs syndrome (RLS). Rotigotine is formulated as a transdermal patch providing continuous drug delivery over 24 h, with a plasma conce...
متن کامل